It’s a Wonderful Banking Life
By Robert Clarke, CEO of Kinaset Therapeutics, as part of the From The Trenches feature of LifeSciVC It’s now been a couple of months since the SVB collapse and the scramble many of us faced during...
View ArticleThe Opportunities Waiting on Big Pharma Shelves
By Mike Cloonan, CEO of Sionna Therapeutics In 2016, following robust discovery efforts by Pfizer and others, the NBD1 domain of the CFTR protein was largely considered undruggable. They knew it was a...
View ArticleOn the Road at ASCO 2023: Key Takeaways, Observations and Reflections
By Amanda J. Redig, SVP and Head of Clinical Development at HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC The American Cancer Society for Oncology (ASCO) annual meeting is...
View ArticleGrowth Mindset for the “Crystallized Intellect”
More Musings from an Old CEO By Natalie Holles, CEO of Third Harmonic Bio, as part of the From The Trenches feature of LifeSciVC The only way we grow as leaders is by stretching the limits of who we...
View ArticleSmooth Transitions: Planning For CEO And Board Succession
By Ankit Mahadevia, Chairman of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC Nobody stays in a particular role forever. While change at the senior level can be disruptive,...
View ArticleClik here to view.
My Love/Hate Relationship with Process
By Aoife Brennan, CEO of Synlogic, as part of the From The Trenches feature of LifeSciVC I remember vividly my first vacation with the man who would be my husband. In the days before Airbnb and...
View ArticleCompany Profile Considerations in A Conservative Cash Environment
By Bob Clarke, CEO of Kinaset Therapeutics, as part of the From The Trenches feature of LifeSciVC As we enter the final leg of 2023, navigating the investment market in biotech continues to be fraught...
View ArticleAtlas Venture 2023 Year In Review
2023 couldn’t end fast enough for most of us in biopharma; its been a tough year in the capital markets, and the industry is facing it’s fair share of headwinds. Fortunately, despite all that, great...
View ArticleDarkest Before Dawn: A Story Of Biotech Optimism In A Tough Market
By Jeb Keiper, CEO of Nimbus Therapeutics, as part of the From The Trenches feature of LifeSciVC. @JebKeiper Earlier this year, Nimbus closed the sale of our allosteric TYK2 program, which was acquired...
View ArticleClik here to view.
Biotech Consolidation: Not Really Happening
After the bursting of the pandemic biotech bubble, talk of industry consolidation was ubiquitous. The sector had pushed out too many IPOs during the go-go years, leading to too many public biotech...
View ArticleClik here to view.
Signaling Complexes: A Ripe Opportunity for Drug Development
By Jonathan Montagu, CEO of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC Signaling pathways are the intricate networks that govern cell behavior, lying at the crux of...
View ArticleClik here to view.
Biotech Venture Ecosystem: Quick Health Check
Biotech feels like it’s got some wind in its sails here at the start of 2024, with positive sentiments from the JPM conference. Indeed, the public equity markets feeling somewhat buoyant for the first...
View ArticleClik here to view.
Sentiment & Themes Emerging From JPM 2024
By Aimee Raleigh, Principal at Atlas Venture, as part of the From The Trenches feature of LifeSciVC Just in time for new years’ reflections and resolutions, this year’s JPM felt like a refreshing burst...
View ArticleThe Long and Winding (Biotech) Road…
By Arthur Tzianabos, CEO of Lifordi Immunotherapeutics, as part of the From the Trenches feature of LifeSciVC Well, this is a first…. while I have read and enjoyed the the LifeSci VC blog for years,...
View ArticleGreater Than The Sum Of The Parts: A Framework For Leading Enterprises In...
By Ankit Mahadevia, former CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC The right leaders in the right structure can power companies to great things. The general...
View ArticleMore than Just Words: Prioritizing Patient-Centered Drug Development
By Ivana Magovčević-Liebisch, CEO of Vigil Neuroscience, as part of the From The Trenches feature of LifeSciVC Patients and their care partners are at the center of our work in the life sciences...
View ArticleMarch Madness – Biotech Style
By Robert Clarke, CEO of Kinaset, as part of the From The Trenches feature of LifeSciVC As I write, I am on the train back from New York after watching my son’s NYU basketball team play in the 2024 D3...
View ArticleEvery Second Counts
By Aoife Brennan, former CEO of Synlogic, as part of the From The Trenches feature of LifeSciVC I have recently completed a turn around the biotech sun: a seven-year assignment at Synlogic that ended...
View ArticleClik here to view.
IFM’s Hat Trick and Reflections On Option-To-Buy M&A
Today IFM Therapeutics announced the acquisition of IFM Due, one of its subsidiaries, by Novartis. Back in Sept 2019, IFM granted Novartis the right to acquire IFM Due as part of an “option to buy”...
View ArticleLessons From A Private Funding Round: Science, Relationships, And Experience
By Mike Cloonan, CEO of Sionna Therapeutics, as part of the From The Trenches feature of LifeSciVC An insightful piece on this blog following the JPM healthcare conference noted the “refreshing burst...
View Article
